Further to an earlier posting about Merck and Elsevier combining on a fake journal, Elsevier now acknowledges that there were six "sponsored article publications."
Elsevier Published Six Fake Journals
May 8, 2009
Share this post
2 Comments

Law Bytes
Ep. 265 – Jason Millar on Claude Mythos, Project Glasswing, and the Governance Crisis in Frontier AI
byMichael Geist

Ep. 265 – Jason Millar on Claude Mythos, Project Glasswing, and the Governance Crisis in Frontier AI
April 20, 2026
Michael Geist
March 30, 2026
Michael Geist
March 16, 2026
Michael Geist
Search Results placeholder
Michael Geist on Substack
Recent Posts
AI Without Canada: Why the Heritage Committee’s AI Report Could Lead to Less Canadian Content in the Training Data
Addressing the AI Policy Challenge: My Appearance before the Standing Senate Committee on Transport and Communications
Lawful Access Heads to Committee: The Opposition Found Its Voice, the Government Never Found Its Defence
Is Data De-Identification Dead?: Why the AI Privacy Risk Isn’t What It Learns, But What It Figures Out
The Law Bytes Podcast, Episode 265: Jason Millar on Claude Mythos, Project Glasswing, and the Governance Crisis in Frontier AI

Use bugmenot to read the article
If you do not want to register just to read an article, use bugmenot.com to enter the-scientist site.
Sick and tired of walled gardens like Elsevier? Support Science Commons
http://sciencecommons.org/about/
Quote:
There are petabytes of research data being produced in laboratories around the world, but the best web search tools available can’t help us make sense of it. Why? Because more stands between basic research and meaningful discovery than the problem of search.
Many scientists today work in relative isolation, left to follow blind alleys and duplicate existing research. Data are balkanized — trapped behind firewalls, locked up by contracts or lost in databases that can’t be accessed or integrated. Materials are hard to get — universities are overwhelmed with transfer requests that ought to be routine, while grant cycles pass and windows of opportunity close. It’s not uncommon for research sponsors to invest hundreds of millions of dollars in critically important efforts like drug discovery, only to see them fail.
The consequences in many cases are no less than tragic. The time it takes to go from identifying a gene to developing a drug currently stands at 17 years — forever, for people suffering from disease.